|
|
FDA Approves Alzheimer's Drug
The entry page to Global Action on Aging's Web site. ... The new medicine, Memantine, works in a different way than the several drugs ...
FDA Approves Memantine (Namenda) for Alzheimer's Disease
... Drug Administration (FDA) today approved memantine (NAMENDA), for ... FDA Commissioner Mark McClellan, M.D., Ph.D. said, "The approval of memantine is ...
memantine (Namenda) - drug class, medical uses, medication side effects ...
Specifies the medication memantine (Namenda), a drug used for the treatment of moderate to ... Memantine was approved by the FDA in October, 2003. ...
Namenda Consumer Information
... Name: Namenda® Active Ingredient: memantine. Strength(s): 5 mg, 10 ... Approval by FDA does not mean that the drug is available for consumers at this time. ...
Fact Sheet: About Memantine
Memantine is classified as an uncompetitive low-to-moderate affinity N-methyl-D ... http://www.fda.gov/ohrms/dockets/ac/cder03.html#PeripheralandCentralNervous System ...
Trends-in-Medicine
unanimously in favor of memantine and Forest on every question posed by the. FDA. ... An FDA official said the ongoing memantine mild/moderate ...
Facts:
Memantine is classified as an uncompetitive low-to-moderate affinity N-methyl-D ... http://www.fda.gov/ohrms/dockets/ac/cder03.html#PeripheralandCentralNervous System ...
FDA approval Memantine - Namenda clinical trails
FDA approval for Memantine - Namenda ... Food and Drug Administration (FDA) approved Memantine for the treatment of Alzheimer's disease. ...
Namenda Official FDA information, side effects and uses.
Accurate, FDA approved Namenda information for healthcare professionals and patients ... FDA > Namenda. Namenda. Generic Name: memantine hydrochloride ...
The Alzheimer's Association of Los Angeles: For Patients and Families
Memantine is classified as an uncompetitive low-to-moderate affinity N-methyl ... In September 2003, the FDA's Peripheral and Central Nervous System Drug Advisory ...
|
|
|
|
Memantine fda |
FDA Approves Memantine (Namenda) for Alzheimer's DiseaseFDA Home Page | Search
FDA Site
| FDA A-Z Index | Contact
FDAThe Food and Drug Administration (FDA) today approved memantine
(NAMENDA), for treatment of moderate to severe Alzheimer’s Disease.
This is the first drug approved for the treatment of patients with
this severity of disease. Previous treatments for Alzheimer’s Disease
have been studied in less severely affected (mild to moderate)
patients. Memantine’s mechanism of action is different from that
of the drugs currently available for treating this disease.The first two double-blind studies, each of about six months duration,
were conducted in the United States, and involved about 250 and
about 400 patients, respectively. The larger study was carried out
in patients already taking donepezil, a drug already approved for
the treatment of Alzheimer’s Disease.
|
Rating: 3.5 èç 5 (ãîëîñîâ: 151) |
|
7 july 2008
Èâàí Ëåðìîíòîâ
|
|
|
|
|
memantine medication
memantine dose
memantine ocd
is memantine
|
|
|
|
|
Forest Laboratories, Inc Q1 2009 Earnings Call Transcript
Seeking Alpha - Apr 21, 2009
The NDA for memantine ER is completed and waiting in the wings as we continue to monitor the patent litigation activities around Namenda. ...
FRX
CATIE-AD: Atypical Antipsychotics Linked to Weight Gain in Older Women
Medscape - Apr 23, 2009
At randomization, 46% were using antihypertensive agents, 60% were taking a cholinesterase inhibitor or memantine, 24% were on cholesterol-lowering ...
Forest Under Fire
Psychiatric Times - Apr 8, 2009
In 1999, according to the complaint, the FDA asked Forest to conduct 2 independent, well-controlled clinical trials in pediatric depression. ...
FRX
|
|
|
|
|